Elisa Agostinetto: Our review on emerging treatments for HER2+ breast cancer

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn:

“Now out in Cell Reports Medicine, our review on emerging treatments for HER2+ breast cancer.

We discuss how survival improvements in this disease set a high bar for new drug development and the need to explore new ways to overcome resistance mechanisms.”